Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 10Leukemia, Biphenotypic, Acute 4Myelodysplastic Syndromes 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 2Waldenstrom Macroglobulinemia 1Recurrence 1Neoplasm, Residual 1Myeloproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Monocytic, Acute 1Leukemia, Hairy Cell 1Leukemia, Erythroblastic, Acute 1Blast Crisis 1

Interventions

Dexamethasone 43Cyclophosphamide 38fludarabine phosphate 27Cytarabine 26Rituximab 24Methotrexate 21Lenalidomide 21Bortezomib 21Calcium Dobesilate 20fludarabine 19Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 16Mycophenolic Acid 16pembrolizumab 15Gemcitabine 15Etoposide 15pomalidomide 14Melphalan 14Vincristine 13Filgrastim 13Busulfan 13Tacrolimus 12Cyclosporine 12Carboplatin 12Paclitaxel 11carfilzomib 10durvalumab 9Doxorubicin 9Cetuximab 9Brentuximab Vedotin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrence × Cladribine × Clear all
NCT00955916 2014-06-27

CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
38 enrolled 8 charts
Other hematologic neoplasm

Blast Crisis, Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡